Exhibit 12.1
OncoGenex Pharmaceuticals, Inc.
Statement of Computation of Ratio of Earnings to Fixed Charges
|
Fiscal Year Ended December 31, |
Six Months Ended June 30, 2015 |
|||||||||||||||||||||||
| (In $000’s, except ratio) |
2010 | 2011 | 2012 | 2013 | 2014 | |||||||||||||||||||
| Fixed Charges: |
||||||||||||||||||||||||
| Interest expense |
$ | 1,172 | $ | 1,086 | $ | 976 | $ | 848 | $ | 699 | $ | 156 | ||||||||||||
| Amortized premiums, discounts and capitalized expenses related to indebtedness |
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| $ | 1,172 | $ | 1,086 | $ | 976 | $ | 848 | $ | 699 | $ | 156 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Earnings (loss): |
||||||||||||||||||||||||
| Net loss before income tax benefit (provision) |
$ | (15,584 | ) | $ | (14,673 | ) | $ | (21,098 | ) | $ | (31,849 | ) | $ | (26,240 | ) | $ | (10,527 | ) | ||||||
| Add fixed charges |
1,172 | 1,086 | 976 | 848 | 699 | 156 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| $ | (14,412 | ) | $ | (13,587 | ) | $ | (20,122 | ) | $ | (31,001 | ) | $ | (25,541 | ) | $ | (10,371 | ) | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Ratio of earnings to fixed charges |
— | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Deficiency of earnings to fixed charges |
$ | (15,584 | ) | $ | (14,673 | ) | $ | (21,098 | ) | $ | (31,849 | ) | $ | (26,240 | ) | $ | (10,527 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||